Natco Pharma
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology. With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Natco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Natco Pharma's score of 29 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Natco Pharma's reported carbon emissions
In 2025, Natco Pharma reported significant carbon emissions, with Scope 1 emissions totalling approximately 23,395,110 kg CO2e and Scope 2 emissions at about 43,630,350 kg CO2e. This data reflects their global operations. In the previous year, 2024, the company recorded Scope 1 emissions of around 31,342,070 kg CO2e and Scope 2 emissions of about 39,945,230 kg CO2e in India. Natco Pharma has set ambitious climate commitments, aiming to enhance renewable energy (RE) in their energy mix to 35% by the end of 2035. This target applies to both Scope 1 and Scope 2 emissions, indicating a long-term strategy to reduce their carbon footprint. The company is currently on track to meet this target within the specified timeframe. While no Scope 3 emissions data has been disclosed, Natco Pharma's focus on renewable energy integration demonstrates a proactive approach to addressing climate change and reducing overall emissions. The company's commitment to sustainability is further supported by their ongoing initiatives to improve energy efficiency and reduce reliance on fossil fuels.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 13,265,000 | 00,000,000 | 000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,696,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Natco Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
